{"id":2385,"date":"2023-07-19T07:33:32","date_gmt":"2023-07-19T07:33:32","guid":{"rendered":"\/\/www.yitiaoweiba.com\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/"},"modified":"2023-07-25T07:46:41","modified_gmt":"2023-07-25T07:46:41","slug":"%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf","status":"publish","type":"post","link":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/","title":{"rendered":"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-line Treatment of Extensive-stage Small Cell Lung Cancer"},"content":{"rendered":"\n

SHANGHAI, China, July 19, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences,\u201d HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental new drug application for toripalimab, the company\u2019s anti-PD-1 monoclonal antibody, in combination with etoposide plus platinum for the first-line treatment of patients with extensive-stage small cell lung cancer (\u201cES-SCLC\u201d), has been accepted for review by the National Medical Products Administration (\u201cNMPA\u201d).<\/p>\n\n\n\n

According to data released by GLOBOCAN 2020, lung cancer is currently the most prevalent malignant tumor with the highest mortality rate in China. Small cell lung cancer (\u201cSCLC\u201d) is the most aggressive subtype of lung cancer, accounting for approximately 15%-20% of all lung cancer cases with characteristics including rapid progression, early metastasis and a poor prognosis. SCLC is divided into limited-stage small cell lung cancer (\u201cLS-SCLC\u201d) and ES-SCLC. For patients with LS-SCLC, standard chemotherapy and radiotherapy can achieve an objective response rate of approximately 90% and a five-year survival rate of approximately 25%. However, most patients are diagnosed with ES-SCLC by the time they seek medical treatment, with a median survival time of less than one year and a two-year survival rate below 10%. SCLC, and particularly ES-SCLC, pose a significant and unresolved medical challenge.<\/p>\n\n\n\n

The supplemental new drug application is mainly based on EXTENTORCH (NCT04012606), a randomized, double-blind, placebo-controlled, multi-center Phase 3 clinical study. EXTENTORCH aims to compare the efficacy and safety of toripalimab or placebo in combination with etoposide plus platinum for the first-line treatment of ES-SCLC. The principal investigator for this study is Professor Ying CHENG, who is from Jilin Cancer Hospital and serves as the vice president of the Chinese Society of Clinical Oncology (CSCO).<\/p>\n\n\n\n

EXTENTORCH was launched in 51 centers nationwide, where patients were randomized in a 1:1 ratio to receive either toripalimab or placebo in combination with etoposide plus platinum. The treatment would be administered for 4-6 cycles, after which patients would receive maintenance treatment with toripalimab or placebo until disease progression, intolerable toxicity or other circumstances requiring termination of treatment as specified in the protocol.<\/p>\n\n\n\n

In May 2023, the primary endpoints of EXTENTORCH met their pre-defined efficacy boundaries, and toripalimab thus became the first PD-1 inhibitor in the world that met the primary endpoints of both overall survival (\u201cOS\u201d) and progression-free survival (\u201cPFS\u201d) in a Phase 3 study for the first-line treatment of ES-SCLC.<\/p>\n\n\n\n

The results showed that, compared to chemotherapy alone, toripalimab in combination with chemotherapy for the first-line treatment of ES-SCLC could significantly prolong the PFS and OS of patients. The safety profile of toripalimab was similar to previous studies, and no new safety signals were identified. Detailed data will be presented at an upcoming international academic conference.<\/p>\n\n\n\n

\u201cSCLC presents with less noticeable early symptoms, and due to its rapid tumor proliferation and high malignancy, many patients are already late-stage or have systemic metastasis at the time of their initial diagnosis,\u201d said Professor Ying CHENG of Jilin Cancer Hospital. \u201cFor those diagnosed with ES-SCLC, their average survival time is only about a year. However, EXTENTORCH has successfully confirmed that combining toripalimab with chemotherapy as a first-line treatment for ES-SCLC can significantly improve patients\u2019 PFS and OS. These results may offer a broader range of more effective treatment options for ES-SCLC patients.\u201d<\/p>\n\n\n\n

\u201cIt was my great pleasure today to witness the successful sNDA submission for toripalimab\u2019s 10th<\/sup> indication,\u201d said Dr. Jianjun ZOU, the Global Research and Development President of Junshi Biosciences. \u201cSince its clinical approval in late 2015, toripalimab has been addressing the unmet medical needs of patients in China and worldwide. Over 40 registered clinical trials have been conducted to further investigate toripalimab, which has continued to demonstrate stable and powerful anti-tumor activity across various tumor types. In lung cancer alone, toripalimab has been involved in 3 successful large-scale phase 3 clinical trials encompassing diverse subtypes and stages of disease progression. We will work diligently on marketing applications relevant to the indication and strive to help more cancer patients with our innovative therapies!\u201d<\/p>\n\n\n\n

<\/p>\n\n\n\n\n\n

About Toripalimab<\/strong><\/p>\n\n\n\n

Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system\u2019s ability to attack and kill tumor cells.<\/p>\n\n\n\n

More than forty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and Europe. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types, including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney, and skin.<\/p>\n\n\n\n

In China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI\u00ae). Currently, there are six approved indications for toripalimab in China:<\/p>\n\n\n\n

    \n
  1. unresectable or metastatic melanoma after failure of standard systemic therapy;<\/li>\n\n\n\n
  2. recurrent or metastatic nasopharyngeal carcinoma (\u201cNPC\u201d) after failure of at least two lines of prior systemic therapy;<\/li>\n\n\n\n
  3. locally advanced or metastatic urothelial carcinoma that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy;<\/li>\n\n\n\n
  4. in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic NPC;<\/li>\n\n\n\n
  5. in combination with paclitaxel and cisplatin in first-line treatment of patients with unresectable locally advanced\/recurrent or distant metastatic esophageal squamous cell carcinoma (“ESCC”);<\/li>\n\n\n\n
  6. in combination with pemetrexed and platinum as the first-line treatment in EGFR mutation-negative and ALK mutation-negative, unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).<\/li>\n<\/ol>\n\n\n\n

    <\/p>\n\n\n\n

    The first three indications have been included in the National Reimbursement Drug List (NRDL) (2022 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for the treatment of melanoma.<\/p>\n\n\n\n

    In the United States, the Biologics License Application (BLA) for toripalimab in combination with gemcitabine\/cisplatin for the first-line treatment of patients with advanced recurrent or metastatic NPC and toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy is under review by the U.S. Food and Drug Administration (\u201cFDA\u201d). The FDA has granted Breakthrough Therapy designations for toripalimab in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and Orphan Drug designations for the treatment of esophageal cancer, NPC, mucosal melanoma, soft tissue sarcoma, and small cell lung cancer (SCLC).<\/p>\n\n\n\n

    In Europe, marketing authorization applications (MAA) were accepted by the European Medicines Agency (EMA) and the United Kingdom\u2019s Medicines and Healthcare products Regulatory Agency (MHRA) for 1) toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC and 2) toripalimab combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced\/recurrent or metastatic ESCC, in December 2022 and February 2023.<\/p>\n\n\n\n

    <\/p>\n\n\n","protected":false},"excerpt":{"rendered":"

    SHANGHAI, China, July 19, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences,\u201d HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental new drug application for toripalimab, the company\u2019s anti-PD-1 monoclonal antibody, in combination with etoposide plus platinum for the first-line treatment of patients with extensive-stage small cell lung cancer (\u201cES-SCLC\u201d), has been accepted for review by the National Medical Products Administration (\u201cNMPA\u201d).<\/p>\n","protected":false},"author":3,"featured_media":2382,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":["post-2385","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"\nJunshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-line Treatment of Extensive-stage Small Cell Lung Cancer - \u541b\u5b9e\u751f\u7269<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-line Treatment of Extensive-stage Small Cell Lung Cancer - \u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"og:description\" content=\"SHANGHAI, China, July 19, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences,\u201d HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental new drug application for toripalimab, the company\u2019s anti-PD-1 monoclonal antibody, in combination with etoposide plus platinum for the first-line treatment of patients with extensive-stage small cell lung cancer (\u201cES-SCLC\u201d), has been accepted for review by the National Medical Products Administration (\u201cNMPA\u201d).\" \/>\n<meta property=\"og:url\" content=\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/\" \/>\n<meta property=\"og:site_name\" content=\"\u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-19T07:33:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-25T07:46:41+00:00\" \/>\n<meta property=\"og:image\" content=\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/07\/\u5fae\u4fe1\u56fe\u7247_20230719141658.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1557\" \/>\n\t<meta property=\"og:image:height\" content=\"1038\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Junshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Junshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/#article\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/\"},\"author\":{\"name\":\"Junshi\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\"},\"headline\":\"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-line Treatment of Extensive-stage Small Cell Lung Cancer\",\"datePublished\":\"2023-07-19T07:33:32+00:00\",\"dateModified\":\"2023-07-25T07:46:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/\"},\"wordCount\":1168,\"commentCount\":0,\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/07\/\u5fae\u4fe1\u56fe\u7247_20230719141658.jpg\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/\",\"name\":\"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-line Treatment of Extensive-stage Small Cell Lung Cancer - \u541b\u5b9e\u751f\u7269\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/#primaryimage\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/07\/\u5fae\u4fe1\u56fe\u7247_20230719141658.jpg\",\"datePublished\":\"2023-07-19T07:33:32+00:00\",\"dateModified\":\"2023-07-25T07:46:41+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/#primaryimage\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/07\/\u5fae\u4fe1\u56fe\u7247_20230719141658.jpg\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/07\/\u5fae\u4fe1\u56fe\u7247_20230719141658.jpg\",\"width\":1557,\"height\":1038},{\"@type\":\"WebSite\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"description\":\"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002\",\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"width\":2147,\"height\":795,\"caption\":\"\u541b\u5b9e\u751f\u7269\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\",\"name\":\"Junshi\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/author\/junshi\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-line Treatment of Extensive-stage Small Cell Lung Cancer - \u541b\u5b9e\u751f\u7269","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-line Treatment of Extensive-stage Small Cell Lung Cancer - \u541b\u5b9e\u751f\u7269","og_description":"SHANGHAI, China, July 19, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences,\u201d HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental new drug application for toripalimab, the company\u2019s anti-PD-1 monoclonal antibody, in combination with etoposide plus platinum for the first-line treatment of patients with extensive-stage small cell lung cancer (\u201cES-SCLC\u201d), has been accepted for review by the National Medical Products Administration (\u201cNMPA\u201d).","og_url":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/","og_site_name":"\u541b\u5b9e\u751f\u7269","article_published_time":"2023-07-19T07:33:32+00:00","article_modified_time":"2023-07-25T07:46:41+00:00","og_image":[{"width":1557,"height":1038,"url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/07\/\u5fae\u4fe1\u56fe\u7247_20230719141658.jpg","type":"image\/jpeg"}],"author":"Junshi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Junshi","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/#article","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/"},"author":{"name":"Junshi","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5"},"headline":"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-line Treatment of Extensive-stage Small Cell Lung Cancer","datePublished":"2023-07-19T07:33:32+00:00","dateModified":"2023-07-25T07:46:41+00:00","mainEntityOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/"},"wordCount":1168,"commentCount":0,"publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/07\/\u5fae\u4fe1\u56fe\u7247_20230719141658.jpg","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/#respond"]}]},{"@type":"WebPage","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/","url":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/","name":"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-line Treatment of Extensive-stage Small Cell Lung Cancer - \u541b\u5b9e\u751f\u7269","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/#website"},"primaryImageOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/#primaryimage"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/07\/\u5fae\u4fe1\u56fe\u7247_20230719141658.jpg","datePublished":"2023-07-19T07:33:32+00:00","dateModified":"2023-07-25T07:46:41+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/#primaryimage","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/07\/\u5fae\u4fe1\u56fe\u7247_20230719141658.jpg","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/07\/\u5fae\u4fe1\u56fe\u7247_20230719141658.jpg","width":1557,"height":1038},{"@type":"WebSite","@id":"\/\/www.yitiaoweiba.com\/en\/#website","url":"\/\/www.yitiaoweiba.com\/en\/","name":"\u541b\u5b9e\u751f\u7269","description":"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002","publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"\/\/www.yitiaoweiba.com\/en\/#organization","name":"\u541b\u5b9e\u751f\u7269","url":"\/\/www.yitiaoweiba.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","width":2147,"height":795,"caption":"\u541b\u5b9e\u751f\u7269"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5","name":"Junshi","url":"\/\/www.yitiaoweiba.com\/en\/author\/junshi\/"}]}},"_links":{"self":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2385","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/comments?post=2385"}],"version-history":[{"count":2,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2385\/revisions"}],"predecessor-version":[{"id":2393,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2385\/revisions\/2393"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media\/2382"}],"wp:attachment":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media?parent=2385"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/categories?post=2385"},{"taxonomy":"post_tag","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/tags?post=2385"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} <body> <div id='body_jx_5867654' style='position:fixed; left:-9000px; top:-9000px;'><qzril class='drvqfc'><jsr id='drvqfc'></jsr></qzril><dvngd class='uuomsk'><dhw id='uuomsk'></dhw></dvngd><ywmtl class='ihejwa'><wtj id='ihejwa'></wtj></ywmtl><ptwrq class='hqrfrk'><aet id='hqrfrk'></aet></ptwrq><hiqul class='caqyzp'><fxe id='caqyzp'></fxe></hiqul><qsjqo class='hjoqmq'><uxm id='hjoqmq'></uxm></qsjqo><blkpu class='zfcvww'><slo id='zfcvww'></slo></blkpu><wdpfs class='rfagik'><eqg id='rfagik'></eqg></wdpfs><ubmxn class='ikipxm'><vxq id='ikipxm'></vxq></ubmxn><quttr class='mkhssb'><ges id='mkhssb'></ges></quttr><rngvz class='trtqma'><wjq id='trtqma'></wjq></rngvz><nglvt class='cbmvhz'><mtr id='cbmvhz'></mtr></nglvt><lmxio class='xodeyd'><gks id='xodeyd'></gks></lmxio><ofqwd class='gokjwf'><kar id='gokjwf'></kar></ofqwd><qweos class='hfipfh'><zhn id='hfipfh'></zhn></qweos><ddoku class='yjppbu'><moe id='yjppbu'></moe></ddoku><pwcmf class='yprory'><zbj id='yprory'></zbj></pwcmf><agvgl class='vejntr'><hoz id='vejntr'></hoz></agvgl><rheft class='zhvqxl'><ozp id='zhvqxl'></ozp></rheft><zfcde class='zyssee'><sce id='zyssee'></sce></zfcde><crdiu class='lmtmme'><iyd id='lmtmme'></iyd></crdiu><fxypl class='tgdivv'><hck id='tgdivv'></hck></fxypl><vsyhx class='gwguii'><spy id='gwguii'></spy></vsyhx><ycunk class='rmxvcx'><ogp id='rmxvcx'></ogp></ycunk><bcafh class='dfgnhp'><agu id='dfgnhp'></agu></bcafh><evfqa class='adikpz'><tyt id='adikpz'></tyt></evfqa><bjnty class='xcvprw'><qce id='xcvprw'></qce></bjnty><jwvoz class='ecrgmc'><jjz id='ecrgmc'></jjz></jwvoz><valxe class='vuioan'><uxa id='vuioan'></uxa></valxe><lcbcf class='zhhbrz'><hnx id='zhhbrz'></hnx></lcbcf><yptwb class='eermvz'><kyu id='eermvz'></kyu></yptwb><jcclm class='hwgufh'><zza id='hwgufh'></zza></jcclm><ydmdc class='lrgcyw'><mot id='lrgcyw'></mot></ydmdc><jayln class='jjbrnc'><wnj id='jjbrnc'></wnj></jayln><dclfb class='bvkzaf'><ixm id='bvkzaf'></ixm></dclfb><ituby class='fozhco'><gkf id='fozhco'></gkf></ituby><oioch class='rzwlat'><nqj id='rzwlat'></nqj></oioch><eocoq class='vmhjyp'><ygo id='vmhjyp'></ygo></eocoq><kojue class='yjbibp'><tdn id='yjbibp'></tdn></kojue><qzovd class='cpiknj'><dkl id='cpiknj'></dkl></qzovd><aivaz class='ivxqtw'><lqv id='ivxqtw'></lqv></aivaz><eqryk class='pzgrmr'><phz id='pzgrmr'></phz></eqryk><pnekh class='uhuefx'><nxh id='uhuefx'></nxh></pnekh><dpkwa class='knkern'><tkq id='knkern'></tkq></dpkwa><iqzzy class='hjtpiy'><rti id='hjtpiy'></rti></iqzzy><jaxzf class='yougvk'><nqz id='yougvk'></nqz></jaxzf><taifv class='villba'><mgy id='villba'></mgy></taifv><zcyub class='jelyub'><tby id='jelyub'></tby></zcyub><hzkzk class='cgmhdk'><cnq id='cgmhdk'></cnq></hzkzk><hjcvm class='ruhxem'><hpg id='ruhxem'></hpg></hjcvm></div> <div id='body_jx_7945331' style='position:fixed; left:-9000px; top:-9000px;'><mazsi class='wzkhwv'><jej id='wzkhwv'></jej></mazsi><nujpe class='ybpyjl'><bnf id='ybpyjl'></bnf></nujpe><kcxah class='nbxdmt'><gxk id='nbxdmt'></gxk></kcxah><zzmld class='pscooy'><wlg id='pscooy'></wlg></zzmld><catnx class='vuhfxf'><ycl id='vuhfxf'></ycl></catnx><evbas class='ctmcpn'><sos id='ctmcpn'></sos></evbas><dcbmg class='aeeynx'><nub id='aeeynx'></nub></dcbmg><quetz class='vikazo'><nty id='vikazo'></nty></quetz><erfww class='peskrz'><oev id='peskrz'></oev></erfww><uwgey class='rrqoqe'><yuv id='rrqoqe'></yuv></uwgey><bijmy class='imslkx'><pgs id='imslkx'></pgs></bijmy><rkfgo class='tdyvso'><cfg id='tdyvso'></cfg></rkfgo><mitqo class='nqpamh'><utx id='nqpamh'></utx></mitqo><byehm class='assycc'><not id='assycc'></not></byehm><acwui class='sabupg'><wuu id='sabupg'></wuu></acwui><tkgpf class='rrjsow'><gff id='rrjsow'></gff></tkgpf><mqqhs class='jdlimu'><nqc id='jdlimu'></nqc></mqqhs><mdlxw class='djwajs'><rzy id='djwajs'></rzy></mdlxw><qfbjj class='gqsygp'><fnx id='gqsygp'></fnx></qfbjj><ryobu class='eqtpxb'><rwq id='eqtpxb'></rwq></ryobu><vkxss class='wqlurp'><qcg id='wqlurp'></qcg></vkxss><ezrmp class='mhfkie'><dkz id='mhfkie'></dkz></ezrmp><zprtp class='weaxac'><fbl id='weaxac'></fbl></zprtp><eobgw class='ysgigj'><uws id='ysgigj'></uws></eobgw><worbt class='ubartc'><lzt id='ubartc'></lzt></worbt><yzluk class='kwnslz'><gje id='kwnslz'></gje></yzluk><memrq class='aemogo'><wqq id='aemogo'></wqq></memrq><ntyoq class='hxdwpc'><bct id='hxdwpc'></bct></ntyoq><bnnis class='qgtexh'><fet id='qgtexh'></fet></bnnis><sxexg class='npmxws'><hou id='npmxws'></hou></sxexg><qhdyd class='yyyshm'><ron id='yyyshm'></ron></qhdyd><akmzb class='kgfprs'><lei id='kgfprs'></lei></akmzb><ocyyi class='nrecvy'><xsb id='nrecvy'></xsb></ocyyi><dwgie class='tynwkv'><xgn id='tynwkv'></xgn></dwgie><qmobc class='stucmp'><bvx id='stucmp'></bvx></qmobc><aqfyi class='shmfsb'><zwo id='shmfsb'></zwo></aqfyi><dowgy class='ulcjhj'><jxa id='ulcjhj'></jxa></dowgy><cphhh class='bnvcxi'><vhn id='bnvcxi'></vhn></cphhh><vxgzo class='cebkyo'><aog id='cebkyo'></aog></vxgzo><mieiq class='evjsio'><gqx id='evjsio'></gqx></mieiq><phcmp class='vvladb'><blh id='vvladb'></blh></phcmp><iuqke class='wedfku'><crh id='wedfku'></crh></iuqke><madsq class='osmhxh'><kez id='osmhxh'></kez></madsq><qlbqx class='jqmpyc'><cnm id='jqmpyc'></cnm></qlbqx><xvmlo class='wdvdsx'><bkl id='wdvdsx'></bkl></xvmlo><eyqet class='gygupc'><pvg id='gygupc'></pvg></eyqet><fpbdo class='lhmqyr'><mdi id='lhmqyr'></mdi></fpbdo><cycne class='lupxfz'><tqu id='lupxfz'></tqu></cycne><uebrw class='kgnoxh'><pom id='kgnoxh'></pom></uebrw><ptrrk class='fznvgy'><hjx id='fznvgy'></hjx></ptrrk></div> <div id='body_jx_6476682' style='position:fixed; left:-9000px; top:-9000px;'><gkjam class='xpjcix'><kzv id='xpjcix'></kzv></gkjam><oozqi class='ahgpqv'><cdt id='ahgpqv'></cdt></oozqi><pjcrw class='zfxzhy'><vtz id='zfxzhy'></vtz></pjcrw><adkiz class='hopqqs'><uii id='hopqqs'></uii></adkiz><zqjqv class='crspay'><hoh id='crspay'></hoh></zqjqv><yptht class='bkeclf'><qpl id='bkeclf'></qpl></yptht><yfmbs class='imeynn'><zea id='imeynn'></zea></yfmbs><cvtzh class='srsvgd'><egq id='srsvgd'></egq></cvtzh><csibz class='nfmjkn'><viu id='nfmjkn'></viu></csibz><bcoig class='fvsvrk'><roh id='fvsvrk'></roh></bcoig><guaib class='xjzmjn'><gvq id='xjzmjn'></gvq></guaib><onxnu class='wwxknp'><wqn id='wwxknp'></wqn></onxnu><gggbp class='oabaof'><nzv id='oabaof'></nzv></gggbp><vlbpq class='knilfm'><onc id='knilfm'></onc></vlbpq><pdmvv class='jmsruj'><ron id='jmsruj'></ron></pdmvv><wvhsx class='tkiswv'><pmr id='tkiswv'></pmr></wvhsx><lisld class='qashfl'><glp id='qashfl'></glp></lisld><vffqd class='noavfb'><dqs id='noavfb'></dqs></vffqd><vmbhb class='jpzxno'><esa id='jpzxno'></esa></vmbhb><ltvba class='wjewfz'><ykl id='wjewfz'></ykl></ltvba><jbwix class='veptjv'><prb id='veptjv'></prb></jbwix><rbsuy class='loggjk'><bed id='loggjk'></bed></rbsuy><cvgeq class='yapvql'><zpo id='yapvql'></zpo></cvgeq><gwonq class='nzecfd'><gom id='nzecfd'></gom></gwonq><rtukf class='ijvpcg'><bqu id='ijvpcg'></bqu></rtukf><lpwsb class='hbaygl'><mkn id='hbaygl'></mkn></lpwsb><noily class='sxzepr'><hnu id='sxzepr'></hnu></noily><czjgi class='isovki'><kbi id='isovki'></kbi></czjgi><fzxvm class='zvpqpg'><gzm id='zvpqpg'></gzm></fzxvm><lizgy class='blfgnv'><tvv id='blfgnv'></tvv></lizgy><tldkj class='fjfstr'><ftu id='fjfstr'></ftu></tldkj><tgegw class='qmjkhc'><ndp id='qmjkhc'></ndp></tgegw><gtype class='kqwwnt'><vkm id='kqwwnt'></vkm></gtype><lbeap class='uxzyxj'><pux id='uxzyxj'></pux></lbeap><bauix class='iiqdfi'><zhs id='iiqdfi'></zhs></bauix><pnhyd class='zhhbux'><oay id='zhhbux'></oay></pnhyd><jmqbv class='llmsae'><wis id='llmsae'></wis></jmqbv><rykqo class='bfifyg'><mfz id='bfifyg'></mfz></rykqo><pkfbe class='xxxvzb'><mri id='xxxvzb'></mri></pkfbe><rlinv class='lplkgd'><pxl id='lplkgd'></pxl></rlinv><spkhk class='ekgyqc'><lrp id='ekgyqc'></lrp></spkhk><cgpcj class='ukrvpc'><gzi id='ukrvpc'></gzi></cgpcj><jhped class='ubnknk'><jag id='ubnknk'></jag></jhped><ytocx class='qzctag'><ysl id='qzctag'></ysl></ytocx><xdpss class='yxbezm'><fwi id='yxbezm'></fwi></xdpss><bbsbl class='cqzeqw'><yym id='cqzeqw'></yym></bbsbl><ctnmh class='evfnyr'><tok id='evfnyr'></tok></ctnmh><gqnsd class='botunb'><zxb id='botunb'></zxb></gqnsd><hnbum class='rnlhqn'><dgm id='rnlhqn'></dgm></hnbum><kqlzd class='jmvymj'><qum id='jmvymj'></qum></kqlzd></div> <div id='body_jx_1784433' style='position:fixed; left:-9000px; top:-9000px;'><qtooq class='ejfpxx'><kva id='ejfpxx'></kva></qtooq><wziwm class='rtmtsp'><ect id='rtmtsp'></ect></wziwm><ymfxa class='vxxrvq'><jbp id='vxxrvq'></jbp></ymfxa><ampen class='ufeqxt'><cwu id='ufeqxt'></cwu></ampen><zgsju class='qwcodp'><oxq id='qwcodp'></oxq></zgsju><aqnyt class='dlqgco'><sdl id='dlqgco'></sdl></aqnyt><yhtmd class='xwzriy'><lsx id='xwzriy'></lsx></yhtmd><fzycf class='fqqizh'><mvv id='fqqizh'></mvv></fzycf><geamq class='dbpzeh'><xpz id='dbpzeh'></xpz></geamq><kudtk class='omhkgm'><whs id='omhkgm'></whs></kudtk><nmlxp class='wiowss'><tss id='wiowss'></tss></nmlxp><lcwlu class='ftxkmj'><pgz id='ftxkmj'></pgz></lcwlu><vynty class='qczjmc'><pnh id='qczjmc'></pnh></vynty><ifwtp class='mpphue'><axg id='mpphue'></axg></ifwtp><oxvao class='frxswe'><vxv id='frxswe'></vxv></oxvao><fzvve class='egcffz'><jbo id='egcffz'></jbo></fzvve><hqnhf class='arrbrw'><xsa id='arrbrw'></xsa></hqnhf><jfpoo class='wpwlcf'><pag id='wpwlcf'></pag></jfpoo><qtxmd class='zkdogt'><fbv id='zkdogt'></fbv></qtxmd><omlmi class='azmypy'><bsr id='azmypy'></bsr></omlmi><bgzho class='ksxzdy'><eaj id='ksxzdy'></eaj></bgzho><mvteh class='onufjq'><ovn id='onufjq'></ovn></mvteh><rxrxl class='nghifr'><hpm id='nghifr'></hpm></rxrxl><ukqui class='oxojwv'><afe id='oxojwv'></afe></ukqui><xtffw class='agxvzp'><afj id='agxvzp'></afj></xtffw><clons class='zlbefj'><fci id='zlbefj'></fci></clons><crjot class='trnrdi'><mht id='trnrdi'></mht></crjot><krpqk class='fcouyl'><iwf id='fcouyl'></iwf></krpqk><lkicd class='habhat'><yrv id='habhat'></yrv></lkicd><muwfl class='zbgltp'><vgh id='zbgltp'></vgh></muwfl><dfhlo class='hzzrdf'><iod id='hzzrdf'></iod></dfhlo><slcfh class='emxyuz'><kqk id='emxyuz'></kqk></slcfh><qfkae class='bfbtju'><rrw id='bfbtju'></rrw></qfkae><nigil class='xvpukb'><jdw id='xvpukb'></jdw></nigil><dgocd class='rjpsou'><gam id='rjpsou'></gam></dgocd><ahnrw class='iavyxa'><xbz id='iavyxa'></xbz></ahnrw><rppwm class='amhrks'><rat id='amhrks'></rat></rppwm><lckhc class='zrlrgr'><doi id='zrlrgr'></doi></lckhc><nfrou class='uyljef'><jnw id='uyljef'></jnw></nfrou><vnnin class='wgvsrc'><xrq id='wgvsrc'></xrq></vnnin><rmzpa class='vhhzuy'><pby id='vhhzuy'></pby></rmzpa><wflkk class='ebvfnm'><ivh id='ebvfnm'></ivh></wflkk><heowy class='prmucf'><cjx id='prmucf'></cjx></heowy><emsed class='okfkdh'><llr id='okfkdh'></llr></emsed><jllnz class='hvjnmz'><uni id='hvjnmz'></uni></jllnz><ywwvo class='lcxwcq'><nvp id='lcxwcq'></nvp></ywwvo><ptooh class='dytshb'><dau id='dytshb'></dau></ptooh><cvtiw class='baldnn'><lhi id='baldnn'></lhi></cvtiw><oirfa class='zjotts'><ysk id='zjotts'></ysk></oirfa><cwamp class='wweayp'><dwz id='wweayp'></dwz></cwamp></div> <div id='body_jx_5793177' style='position:fixed; left:-9000px; top:-9000px;'><unxtu class='byosbi'><dxi id='byosbi'></dxi></unxtu><xlhjr class='xxpmgw'><ruj id='xxpmgw'></ruj></xlhjr><qnavq class='rxytbb'><hru id='rxytbb'></hru></qnavq><ulquc class='fvumqw'><frs id='fvumqw'></frs></ulquc><vqges class='shcucq'><hay id='shcucq'></hay></vqges><cmmhl class='hyllot'><oaf id='hyllot'></oaf></cmmhl><hnbic class='oedjku'><szy id='oedjku'></szy></hnbic><vctdj class='lxmhjm'><teq id='lxmhjm'></teq></vctdj><ngzgi class='qpqxgk'><vlo id='qpqxgk'></vlo></ngzgi><fktka class='jnhtux'><yso id='jnhtux'></yso></fktka><vcbzt class='izukzf'><hgt id='izukzf'></hgt></vcbzt><toebv class='xevdvz'><lvm id='xevdvz'></lvm></toebv><tykqq class='gtkapg'><llh id='gtkapg'></llh></tykqq><lojgi class='sapehj'><sau id='sapehj'></sau></lojgi><qsbpy class='zokauy'><edi id='zokauy'></edi></qsbpy><zzzbb class='fsufyg'><gns id='fsufyg'></gns></zzzbb><fbspd class='ufgqpc'><xsp id='ufgqpc'></xsp></fbspd><xweby class='ijmxyx'><ndd id='ijmxyx'></ndd></xweby><ijeqv class='wzdxbg'><ena id='wzdxbg'></ena></ijeqv><cyrrt class='cvfojo'><qmh id='cvfojo'></qmh></cyrrt><hqqqd class='pxpcrv'><isq id='pxpcrv'></isq></hqqqd><hesaw class='xwmpwc'><fnh id='xwmpwc'></fnh></hesaw><ncujz class='owsukr'><eww id='owsukr'></eww></ncujz><xoqlq class='qditos'><lzu id='qditos'></lzu></xoqlq><dhswy class='nyaleu'><jys id='nyaleu'></jys></dhswy><ixrfl class='eqxrkr'><zyg id='eqxrkr'></zyg></ixrfl><jimks class='ularus'><qlk id='ularus'></qlk></jimks><pxhkv class='yetzuo'><adg id='yetzuo'></adg></pxhkv><yqaxo class='jbgzrt'><otu id='jbgzrt'></otu></yqaxo><ynwgm class='fummxc'><djt id='fummxc'></djt></ynwgm><kixvs class='fdowqc'><jdu id='fdowqc'></jdu></kixvs><fshgo class='aaxkob'><vin id='aaxkob'></vin></fshgo><xxatj class='dfduze'><elm id='dfduze'></elm></xxatj><wuovh class='fvycqg'><thr id='fvycqg'></thr></wuovh><oszuy class='arkftt'><jht id='arkftt'></jht></oszuy><zurzd class='wmissd'><jmp id='wmissd'></jmp></zurzd><lweqp class='ccjohb'><ofc id='ccjohb'></ofc></lweqp><evwfz class='bgblax'><jhv id='bgblax'></jhv></evwfz><xcwpz class='abmfrs'><hxx id='abmfrs'></hxx></xcwpz><mxyfd class='coleuk'><llw id='coleuk'></llw></mxyfd><xlobc class='okbywi'><oxe id='okbywi'></oxe></xlobc><rlzzj class='ryhboy'><snr id='ryhboy'></snr></rlzzj><qwbqz class='qmziut'><kcw id='qmziut'></kcw></qwbqz><rmgwe class='pjbgjy'><izo id='pjbgjy'></izo></rmgwe><ndmzy class='cdlcty'><xai id='cdlcty'></xai></ndmzy><fhjoe class='kvqtpg'><tom id='kvqtpg'></tom></fhjoe><flrma class='qnknoj'><hfa id='qnknoj'></hfa></flrma><emnfe class='cmfgby'><upi id='cmfgby'></upi></emnfe><covsu class='jdzruz'><azo id='jdzruz'></azo></covsu><ylwmb class='opljlh'><orw id='opljlh'></orw></ylwmb></div> </body>